[{"address1": "3891 Ranchero Drive", "address2": "Suite 150", "city": "Ann Arbor", "state": "MI", "zip": "48108", "country": "United States", "phone": "734 887 3903", "website": "https://www.esperion.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.", "fullTimeEmployees": 240, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sheldon L. Koenig", "age": 57, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1278804, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. JoAnne Micale Foody FACC, M.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 856871, "exercisedValue": 0, "unexercisedValue": 3822}, {"maxAge": 1, "name": "Mr. Eric J. Warren R.Ph.", "age": 51, "title": "Chief Commercial Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 718859, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Halladay M.B.A.", "age": 37, "title": "Chief Financial Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Glenn P. Brame", "age": 65, "title": "Chief Technical Operations Officer", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin O. Looker J.D.", "age": 41, "title": "General Counsel & Corporate Secretary", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 550350, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Tiffany  Aldrich M.B.A.", "title": "Associate Director of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Betty Jean Swartz", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1711929600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.13, "open": 2.11, "dayLow": 1.95, "dayHigh": 2.1, "regularMarketPreviousClose": 2.13, "regularMarketOpen": 2.11, "regularMarketDayLow": 1.95, "regularMarketDayHigh": 2.1, "beta": 0.822, "forwardPE": 39.8, "volume": 5053303, "regularMarketVolume": 5053303, "averageVolume": 6255695, "averageVolume10days": 5812530, "averageDailyVolume10Day": 5812530, "bid": 1.97, "ask": 1.99, "bidSize": 2600, "askSize": 100, "marketCap": 376907968, "fiftyTwoWeekLow": 0.7, "fiftyTwoWeekHigh": 3.4, "priceToSalesTrailing12Months": 3.239878, "fiftyDayAverage": 2.416, "twoHundredDayAverage": 1.78745, "currency": "USD", "enterpriseValue": 826953856, "profitMargins": -1.79868, "floatShares": 184027513, "sharesOutstanding": 189400992, "sharesShort": 18601646, "sharesShortPriorMonth": 17665969, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.09819999, "heldPercentInsiders": 0.0045, "heldPercentInstitutions": 0.39220002, "shortRatio": 1.95, "shortPercentOfFloat": 0.098500006, "impliedSharesOutstanding": 202724992, "bookValue": -3.849, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -209248000, "trailingEps": -2.03, "forwardEps": 0.05, "pegRatio": -0.31, "enterpriseToRevenue": 7.108, "enterpriseToEbitda": -5.321, "52WeekChange": 0.50757575, "SandP52WeekChange": 0.21080327, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ESPR", "underlyingSymbol": "ESPR", "shortName": "Esperion Therapeutics, Inc.", "longName": "Esperion Therapeutics, Inc.", "firstTradeDateEpochUtc": 1372253400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "00314c6d-38c1-3c8e-a318-bd51d9ba1c8c", "messageBoardId": "finmb_28236", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.99, "targetHighPrice": 16.0, "targetLowPrice": 2.9, "targetMeanPrice": 7.41, "targetMedianPrice": 8.0, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 82248000, "totalCashPerShare": 0.444, "ebitda": -155399008, "totalDebt": 540947008, "quickRatio": 0.837, "currentRatio": 1.287, "totalRevenue": 116334000, "revenuePerShare": 1.128, "returnOnAssets": -0.42856, "freeCashflow": -107141872, "operatingCashflow": -135487008, "revenueGrowth": 0.714, "grossMargins": -0.11209, "ebitdaMargins": -1.3358, "operatingMargins": -1.31371, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-26"}]